Bruce Booth, D.Phil., a partner at Atlas Venture, astutely observed earlier this year that two key resources fueling the growth of biopharma were until recently somewhat geographically spread among the 10 or so regions of the nation where the industry began to arise a generation ago.
“In recent years, this has changed—Boston and San Francisco are now the preeminent biotech clusters. And their gravity in the ecosystem is only getting stronger,” Dr. Booth concluded in a March 21 post on his Life Sci VC blog.
Image: Despite consolidation of capital and talent in the nation’s two largest biopharma clusters, all 10 regions ranked by GEN have significant assets that make them attractive to biopharma researchers, executives, and investors. (Wsvan/Wikimedia)
